Apogee Therapeutics company information, Employees & Contact Information

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress GlobeNewswire

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum Yahoo Finance

Biotech Innovator Apogee Therapeutics Featured at Upcoming Stifel 2025 Immunology Conference Stock Titan

Apogee Therapeutics to Announce Phase 2 APEX Trial Results for APG777 on July 7, 2025 Nasdaq

Apogee Therapeutics: Engineering Biologic Dominance (NASDAQ:APGE) Seeking Alpha

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results GlobeNewswire

Key Phase 2 Data Drop Tomorrow: Apogee's New Atopic Dermatitis Drug Faces Critical Test Stock Titan

Apogee Therapeutics Advances Clinical Pipeline for APG777 and APG279, Reports Strong Cash Position and 2024 Financial Results Nasdaq

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results Yahoo Finance

Breakthrough: Apogee's New Atopic Dermatitis Drug Achieves 71% Efficacy with 6-Month Dosing Potential Stock Titan

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis Yahoo Finance

Apogee Therapeutics Announces R&D Day Agenda Focusing on Innovative Treatment Opportunities in Inflammatory and Immunology Conditions Quiver Quantitative

Apogee's APG777 Achieves 71% Efficacy in Phase 2 Atopic Dermatitis Trial | APGE Stock News Stock Titan

Apogee Therapeutics Advances Phase 1 Clinical Trial for APG333 in Asthma and COPD with Interim Data Expected in 2H 2025 Quiver Quantitative

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering Yahoo Finance

Apogee Therapeutics Closes $345 Million Public Offering of Common Stock and Pre-Funded Warrants Quiver Quantitative

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million Yahoo Finance

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering Yahoo Finance

BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis Yahoo Finance

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results Yahoo Finance

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out Investor's Business Daily

Why Apogee Therapeutics Stock Triumphed on Thursday The Motley Fool

$300M Offering: Apogee Therapeutics Prices 6.95M Shares; Includes Pre-funded Warrants Exercisable Immediately Stock Titan

Apogee Therapeutics' APG990 Demonstrates Extended Half-Life and Favorable Tolerability in Interim Phase 1 Data Dermatology Times

15% Overallotment Option — Apogee Therapeutics Commences Public Offering to Fund Trials Stock Titan

Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? Yahoo Finance

Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? Yahoo Finance

Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors Yahoo Finance

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases GlobeNewswire

How This Small Biotech Is Looking To Take On Sanofi's Cash Cow Investor's Business Daily

Here’s Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 Yahoo Finance

Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis (APGE) Seeking Alpha

Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study PMLiVE

Apogee Therapeutics Appoints Mark C. McKenna as Chairman of its Board citybiz

Apogee Therapeutics Launches with $169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders PR Newswire

Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class (APGE) Seeking Alpha

Apogee Announces Positive Phase 1 Interim Data for APG777 in Atopic Dermatitis, Inflammatory Diseases Dermatology Times

EASI scores fall 71% with APG777 for patients with atopic dermatitis Healio

Apogee Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer PR Newswire

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis Seeking Alpha

Check out Apogee Therapeutics's stock price (APGE) in real time CNBC

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sc Stock Titan

Apogee Therapeutics Strengthens Team with Appointments of Industry Leaders to Board of Directors and Management Business Wire

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference FinancialContent